New River price target upped by Merrill

New River Pharmaceuticals Inc. was maintained by Merrill Lynch analyst David Munno at a buy rating, and Merrill raised its price target on the stock to $56 per share from $49 following positive initial findings from the company's phase I trial of NRP290 for acute pain. New River Pharma shares Tuesday were up $1.35, or 3.18%, at $43.77 on volume of 155,591 shares versus the three-month running average of 78,466.7 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.